Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both for adult and “embryo-safe” human embryonic stem cells) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
ACT’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by Interim President, CFO and Executive Vice President of Corporate Development Ted Myles and Chief Scientific Officer Robert Lanza, M.D.
ACT has three cellular product platforms based on ground-breaking stem cell technology. As documented in the journals Nature and Cell Stem Cell, ACT developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the “single-cell blastomere” technique, on which it holds broad intellectual property (IP) protection. Early results from the first patients treated in ongoing clinical trials of the hESC-based treatment were published in The Lancet.
- The company is focused on commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease, for which it recently initiated two Phase 1/2 clinical trials.
- The company is also developing its human embryonic stem cell (hESC)-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. The company is developing this program in partnership with CHA Biotech of Korea.
- Additionally, the company is developing a method for scaled manufacturing of Mesenchymal Stem Cells (MSCs) from renewable pluripotent stem cell sources. This involves expanding hESC-and IPS-derived MSCs to large numbers in-vitro. MSCs can migrate to injury sites in the eye, exert local immunosuppressive effects, and repair damaged tissue. ACT has a proprietary, scaled manufacturing method for generating “young” MSCs from hESC and iPS lines. This permits the use of a single allogeneic MSC bank to manufacture MSCs. Moreover, hESC- and iPS cell-derived MSCs are far more potent immunomodulators than adult-derived MSCs.
- The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness, as well as retinal neural progenitor cells for use in treating glaucoma.